Absent or limited response to checkpoint inhibitors may not only be the result of a reduced antigenicity (tumor mutation burden, TMB) of the tumor, PD-L1 expression or CD8-T cell density10,12–15, but also to reduced egress of T cells from the bloodstream and influx into the tumor16. This evidence concerns the gene CD274 and neoplasm.